27362 High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the phase 2b core study
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI